Men need to know more about cancerAugust 20, 1999Clare Moynihan and colleagues at the Institute of Cancer Research in Sutton, Surrey reported their research today, Thursday 2 September, at The British Psychological Society's Division of Health Psychology Annual Conference, in Leeds. They interviewed men about their knowledge of prostate and testicular cancer. This included men with cancer, their healthy male relatives, and men with no family history of cancer. All groups demonstrated similar misperceptions. Cancer was viewed as a terminal disease, there was a deep scepticism about its medical management, and screening was understood to be intrusive and aggressive. There was a sense that cancer ran through families, but 'susceptibility' to cancer was thought of as a separate entity related to 'living a health life', and communication between male family members was minimal. This is of major importance as determining the risk of a man getting a genetic cancer, such as prostate or testicular, relies heavily on families talking to each other. However, Clare Moynihan suggests, "Rather than urge men to communicate, there is an urgent need for the transmission of information regarding genetic cancers in ways that men will not find intrusive or intimidating". British Psychological Society (BPS) | |||||||||||||||||||||
|
Related Cancer Current Events and Cancer News Articles Screening for colorectal cancer detects unrecognized disease Screening for colorectal cancer detects four out of ten cancers and should be carefully designed to be more effective, according to a study published today on bmj.com. MU study reveals effective anti-tobacco ads should either scare or disgust viewers Now's the perfect time to increase anti-smoking campaigns - Nov. 20 is the American Cancer Society's Great American Smokeout. Iressa proves just as effective as chemotherapy for lung cancer Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center. Researcher tricks immune system in diabetic mice The body's immune system hates strangers. When its security patrol spots a foreign cell, it annihilates it. Misreading of damaged DNA may spur tumor formation The DNA in our cells is constantly under assault from oxygen, the sun's radiation and environmental stresses. Most of the time, our cells can repair the damage before it gets copied into a permanent mutation that could lead to cancer. A Simple Blood Test for Colon Cancer People are often reluctant to undergo a routine but painful colonoscopy ― but the consequences can be fatal. According to the American Cancer Society, colon cancer is the third most common cancer found in American men and women and kills about 50,000 Americans every year. Systems biology brings hope of speeding up drug development Almost every day brings news of an apparent breakthrough against cancer, infectious diseases, or metabolic conditions like diabetes, but these rarely translate into effective therapies or drugs, and even if they do clinical development usually takes well over a decade. ADHD medications do not cause genetic damage in children In contrast to recent findings, two of the most common medications used to treat attention deficit hyperactivity disorder (ADHD) do not appear to cause genetic damage in children who take them as prescribed, according to a new study by researchers at the National Institutes of Health (NIH) and Duke University Medical Center. New platinum-phosphate compounds kill ovarian cancer cells A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences. Survival of head and neck cancer patients is greatly affected by coexisting ailments Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||